Core Viewpoint - A class action has been filed against Atara Biotherapeutics, Inc. for allegedly misleading investors regarding its drug candidate tabelecleucel, particularly concerning manufacturing issues and regulatory prospects [1][3]. Group 1: Class Action Details - The class period for the action is from May 20, 2024, to January 9, 2026 [3]. - The allegations include failure to disclose manufacturing issues and deficiencies in the ALLELE study, which impacted the likelihood of FDA approval for tabelecleucel [3]. - The complaint states that these undisclosed issues led to a significant negative impact on Atara's business and financial condition, making public statements materially false and misleading [3]. Group 2: Stock Price Impact - On January 12, 2026, Atara announced that the FDA issued a Complete Response Letter (CRL) regarding the tabelecleucel BLA, stating that the trial was inadequate for evidence of effectiveness [4]. - Following this announcement, Atara's stock price fell by $7.79 per share, or 56.99%, closing at $5.88 per share [4]. Group 3: Shareholder Actions - Shareholders may be eligible to participate in the class action and can submit their papers to serve as lead plaintiff by May 22, 2026 [5]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [5].

Core Viewpoint - A class action has been filed against Hercules Capital, Inc. for allegedly misleading investors regarding its due diligence in deal sourcing, loan origination, and portfolio valuation [1][2]. Group 1: Class Action Details - The class period for the action is from May 1, 2025, to February 27, 2026 [2]. - Allegations include overstating due diligence in deal sourcing and loan origination, misclassifying portfolio investments, and misrepresenting portfolio valuations [2]. Group 2: Impact of Allegations - A report published by Hunterbrook Media on February 27, 2026, questioned Hercules Capital's valuation processes and claimed that the company marked its software debt at "100 cents on the dollar" despite significant industry distress [3]. - Following the report, Hercules Capital's stock price dropped by $1.22, or 7.9%, closing at $14.21 per share on the same day [3]. Group 3: Shareholder Actions - Shareholders interested in participating as lead plaintiffs must submit their papers by May 19, 2026 [4]. - Shareholders can choose to remain absent class members without participating in the case [4].

Core Viewpoint - A class action has been filed against Lufax Holding Ltd. for alleged inadequate internal controls and material misstatements in financial reports during the class period from April 7, 2023, to January 26, 2025 [1][2]. Group 1: Allegations and Financial Impact - The allegations include that Lufax made material misstatements in its financial reports and lacked adequate internal controls [2]. - On January 27, 2025, Lufax announced the removal of its auditor, PricewaterhouseCoopers (PwC), due to significant concerns regarding Lufax's financial disclosures, particularly the 2022 and 2023 Annual Reports [3]. - Following the announcement, Lufax's American Depositary Shares (ADSs) fell by $0.40, or 13.8%, closing at $2.49 on January 27, 2025. The next day, the ADSs dropped an additional $0.17, or 6.82%, to close at $2.32, and on January 29, they fell by $0.06, or 2.58%, to close at $2.26 [3]. Group 2: Shareholder Actions - Shareholders may be eligible to participate in the class action against Lufax and must submit their papers to the court by May 20, 2026, if they wish to serve as lead plaintiff [4]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4]. Group 3: Legal Representation - All representation in the class action is on a contingency fee basis, meaning shareholders pay no fees or expenses [5]. - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance [5].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Pinterest (PINS) To Contact Him Directly To Discuss Their Options If you purchased or acquired Pinterest securities between February 7, 2025 and February 12, 2026 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- What’s Happe ...

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin, a novel, first-in-class r ...

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. The Company’s only commercial product is diazoxide choline extended-release tablets (“DCCR”) for the treatment of hyperphagia in individuals afflicted with Prade ...

Core Viewpoint - A class action lawsuit has been filed against Driven Brands Holdings Inc. for allegedly misleading investors about its financial condition during the specified Class Period from May 9, 2023, to February 24, 2026 [1][4]. Company Overview - Driven Brands, headquartered in Charlotte, NC, is the largest automotive services company in North America, offering services such as oil changes, maintenance, collision repair, glass repair, and car wash services through brands like Meineke, Maaco, and Take 5 Oil Change [3]. Legal Allegations - The lawsuit claims that Driven Brands misled investors regarding its financial health, particularly by overstating revenue and cash in previous financial statements, which necessitated restatement [4]. - On February 25, 2026, Driven Brands announced a delay in filing its annual report on Form 10-K for fiscal year 2025 due to "material errors in previously issued financial statements" dating back to 2023 [4]. Market Reaction - Following the disclosure of the financial misstatements, Driven Brands' share price fell nearly 40% [5].

New York, New York--(Newsfile Corp. - March 31, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Power Solutions International, Inc. ("Power Solutions" or the "Company") (NASDAQ: PSIX) between May 8, 2025 and March 2, 2026, inclusive.Should You Join The Power Solutions Class Action Lawsuit?Do you, or did you, own shares of Power Solutions International, Inc. (NASDAQ: PSIX) ...

Core Viewpoint - A class action lawsuit has been filed against Eos Energy Enterprises, Inc. for failing to disclose critical operational issues that affected its financial performance during the specified class period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Eos shares from November 5, 2025, to February 26, 2026 [1][2]. - Investors have until May 5, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Operational Issues - Eos failed to achieve necessary production and capacity utilization to meet previous guidance [3]. - The company's battery line downtime was significantly higher than industry norms [3]. - The automated bipolar production took longer than expected to meet quality targets [3]. - Inadequate systems and processes hindered the company from providing accurate guidance [3]. Group 3: Financial Impact - On February 26, 2026, Eos reported full-year revenue of $114.2 million, which was below the forecast of $150 to $160 million [4]. - The company reported an adjusted EBITDA loss of $219 million [4]. - Following the announcement, Eos shares dropped by $4.39, a decline of over 39%, closing at $6.74 per share [4].

Core Viewpoint - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. for allegedly misleading investors regarding the approval status of its New Drug Application for Anaphylm, leading to significant stock price declines [2][7]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals and entities who purchased or acquired Aquestive securities between June 16, 2025, and January 8, 2026 [2]. - Investors have until May 4, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that during the class period, the defendants created a false impression that Aquestive was on track to receive approval for Anaphylm by the January 31, 2026, Prescription Drug User Fee Act (PDUFA) date [7]. - The FDA identified deficiencies in Aquestive's NDA for Anaphylm, which precluded labeling discussions and delayed the approval process [7]. - Following the announcement of these deficiencies on January 9, 2026, the stock price of Aquestive fell over 37%, from $6.21 per share on January 8, 2026, to $3.91 per share on January 9, 2026 [7]. Group 3: Next Steps for Investors - Investors who suffered losses or have information regarding the case are encouraged to contact the law firm for more details [4]. - There is no cost or obligation for investors to inquire about their rights or interests related to the lawsuit [4]. Group 4: About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation [5]. - The firm has offices in New York, South Carolina, and California, and handles cases in both federal and state courts [5].